| Oct 18 |
Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
|
| Oct 17 |
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
|
| Oct 16 |
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
|
| Oct 16 |
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
|
| Oct 15 |
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
|
| Oct 15 |
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
|
| Oct 15 |
Exelixis gains after win in patent fight with MSN over Cabometyx
|
| Oct 15 |
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
|
| Oct 15 |
Exelixis and MSD to trial cancer therapies together in clinical collaboration
|
| Oct 14 |
Exelixis & Merck sign development collaboration for head, neck cancer treatment and renal cell carcinoma
|
